A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
暂无分享,去创建一个
M. Suarez‐Almazor | P. Tugwell | J. Singh | R. Buchbinder | G. Wells | R. Christensen | E. Ghogomu | M. Lopez‐Olivo | M. Lopez-Olivo
[1] M. Suarez‐Almazor,et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews , 2009, The Cochrane database of systematic reviews.
[2] Jasvinder A Singh,et al. Abatacept for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.
[3] A. Perdriger. Infliximab in the treatment of rheumatoid arthritis , 2009, Biologics : targets & therapy.
[4] J. Singh,et al. Anakinra for rheumatoid arthritis. , 2009, The Cochrane database of systematic reviews.
[5] M. Genovese,et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial , 2008, Annals of the rheumatic diseases.
[6] M. Suarez‐Almazor,et al. Biologics for rheumatoid arthritis , 2009 .
[7] Michael J. Green,et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. , 2008, Arthritis and rheumatism.
[8] A. Oxman,et al. Overviews of Reviews , 2008 .
[9] F. Breedveld,et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.
[10] A. Alonso-Ruiz,et al. Bmc Musculoskeletal Disorders Tumor Necrosis Factor Alpha Drugs in Rheumatoid Arthritis: Systematic Review and Metaanalysis of Efficacy and Safety , 2008 .
[11] N. Miyasaka. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study , 2008, Modern rheumatology.
[12] K. Lohr,et al. Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis , 2008, Annals of Internal Medicine.
[13] M. Dougados,et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2007, Annals of the rheumatic diseases.
[14] Y. Lee,et al. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis , 2008, Rheumatology International.
[15] A. Brennan,et al. PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS , 2007 .
[16] Yeong-Wook Song,et al. A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate , 2007 .
[17] E. Yelin. Work disability in rheumatic diseases , 2007, Current opinion in rheumatology.
[18] David Moher,et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews , 2007, BMC medical research methodology.
[19] V. Bykerk,et al. Etanercept in the treatment of rheumatoid arthritis , 2007, Therapeutics and clinical risk management.
[20] H. Bliddal,et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review , 2007, Scandinavian journal of rheumatology.
[21] J. Kremer,et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial , 2006, Annals of the rheumatic diseases.
[22] K. Lohr,et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. , 2006, The Journal of rheumatology.
[23] Stanley B. Cohen,et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.
[24] H. Genant,et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.
[25] P. Emery,et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.
[26] G G Koch,et al. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities , 2006, Annals of the rheumatic diseases.
[27] B. Hernández-Cruz,et al. Adalimumab for treating rheumatoid arthritis. , 2005, The Journal of rheumatology.
[28] H. Okamoto. Tumor necrosis factor inhibitors for rheumatoid arthritis. , 2006, The New England journal of medicine.
[29] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[30] M. Dougados,et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.
[31] A. Finset,et al. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7‐year study from the Oslo RA register , 2005, Scandinavian journal of rheumatology.
[32] Alexander Fraser,et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.
[33] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[34] P. Emery,et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.
[35] E. Keystone,et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.
[36] M. Genovese,et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. , 2004, Arthritis and rheumatism.
[37] M. Dougados,et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.
[38] L. Moreland,et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate , 2004, Annals of the rheumatic diseases.
[39] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[40] H. Ascher-Svanum,et al. Assessing the value of antipsychotics for treating schizophrenia , 2004, PharmacoEconomics.
[41] V. Strand,et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). , 2003, The Journal of rheumatology.
[42] M. Dougados,et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.
[43] G. Burmester,et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. , 2003, Arthritis and rheumatism.
[44] M. Suarez‐Almazor,et al. Number needed to treat (NNT): implication in rheumatology clinical practice , 2003, Annals of the rheumatic diseases.
[45] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[46] Stanley B. Cohen,et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.
[47] Stanley B. Cohen,et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.
[48] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[49] N Breslow,et al. Generalized linear mixed models for meta-analysis. , 1999, Statistics in medicine.
[50] D. Furst,et al. Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.
[51] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[52] D. Furst,et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.
[53] Z Domljan,et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.
[54] D. Whalley,et al. Quality of life in rheumatoid arthritis. , 1997, British journal of rheumatology.
[55] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[56] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[57] L. T. Swaim. American Rheumatism Association , 1950 .